PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: stock market

Guideline on the exposure to Medicinal Products during ...

European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: EMEA 2005 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged London, 14 November 2005 EMEA/CHMP/313666/2005 COMMITTEE FOR Medicinal Products FOR HUMAN USE (CHMP) Guideline ON THE exposure TO Medicinal Products during PREGNANCY: NEED FOR POST-AUTHORISATION DATA DRAFT AGREED BY AD-HOC EXPERT GROUP, EFFICACY AND PHARMACOVIGILANCE WORKING PARTIES October 2001- June 2004 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION June 2004 END OF CONSULTATION (DEADLINE FOR COMMENTS) December 2004 AGREED BY AD-HOC EXPERT GROUP, EFFICACY AND PHARMACOVIGILANCE WORKING PARTIES September - October 2005 ADOPTION BY CHMP November 2005 DATE FOR COMING INTO EFFECT May 2006 EMEA/CHMP/313666/2005 EMEA 2005 2/21 Guideline ON THE exposure TO Medicinal Products during PREGNANCY.

exposure during the second or third trimester may induce growth retardation, renal insufficiency, neurological disorders, stillbirth, etc. On the other hand, exposure to a teratogenic agent during the first two weeks of pregnancy (3rd and 4th gestational week) may lead either to …

Tags:

  Retardation

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of Guideline on the exposure to Medicinal Products during ...

Related search queries